Abstract
Epithelial-to-Mesenchymal transition (EMT) is a phenomenon in which cancer cells loose their polarity, undergo morphological changes from epithelial to mesenchymal thereby achieving plasticity that confers an invasive and metastatic behavior. A large number of signaling molecules (Wnt/β-Catenin, TGF-β, notch, EGF, HGF and hypoxia) have been implicated in the EMT process. The EMT signaling molecules are localized either extracellularly, in the cytosol, or in the nucleus. The Wnt, TGF-β, notch, EGF and HGF signaling initiates from receptors on the cell surface through the cytoplasm and ultimately to the cell's nucleus where the signaling cascade leads to the expression of EMT genes. No matter what the source is, the ultimate effector molecules from each one of these signaling pathways need to reach cell nucleus, aligning on DNA in a sequence specific manner and initiating the transcription of EMT promoting genes. In essence cellular transport, particularly the nuclear transport that is regulated by specialized proteins called Karyopherins, in a way controls the majority of EMT promoting pathways either directly or indirectly. Nevertheless, there have been no attempts to understand the consequence of alterations in the nuclear transport machinery that is often times aberrantly expressed in cancer, on EMT development. This review poses important questions on the role of nuclear transporters (Importins and Exportins) in the development of EMT and provides an in depth understanding of the underappreciated cellular transport based regulation of EMT signaling molecules and also discusses the possibility of targeting the nuclear import and export proteins to rein in EMT.
Keywords: CRM1, EMT, Epithelial-to-mesenchymal transition, Exportin, Importin, Karyopherin, Nuclear Transport, Xpo1.
Current Cancer Drug Targets
Title:Unveiling the Role of Nuclear Transport in Epithelial-to-Mesenchymal Transition
Volume: 13 Issue: 9
Author(s): Asfar S. Azmi
Affiliation:
Keywords: CRM1, EMT, Epithelial-to-mesenchymal transition, Exportin, Importin, Karyopherin, Nuclear Transport, Xpo1.
Abstract: Epithelial-to-Mesenchymal transition (EMT) is a phenomenon in which cancer cells loose their polarity, undergo morphological changes from epithelial to mesenchymal thereby achieving plasticity that confers an invasive and metastatic behavior. A large number of signaling molecules (Wnt/β-Catenin, TGF-β, notch, EGF, HGF and hypoxia) have been implicated in the EMT process. The EMT signaling molecules are localized either extracellularly, in the cytosol, or in the nucleus. The Wnt, TGF-β, notch, EGF and HGF signaling initiates from receptors on the cell surface through the cytoplasm and ultimately to the cell's nucleus where the signaling cascade leads to the expression of EMT genes. No matter what the source is, the ultimate effector molecules from each one of these signaling pathways need to reach cell nucleus, aligning on DNA in a sequence specific manner and initiating the transcription of EMT promoting genes. In essence cellular transport, particularly the nuclear transport that is regulated by specialized proteins called Karyopherins, in a way controls the majority of EMT promoting pathways either directly or indirectly. Nevertheless, there have been no attempts to understand the consequence of alterations in the nuclear transport machinery that is often times aberrantly expressed in cancer, on EMT development. This review poses important questions on the role of nuclear transporters (Importins and Exportins) in the development of EMT and provides an in depth understanding of the underappreciated cellular transport based regulation of EMT signaling molecules and also discusses the possibility of targeting the nuclear import and export proteins to rein in EMT.
Export Options
About this article
Cite this article as:
Azmi S. Asfar, Unveiling the Role of Nuclear Transport in Epithelial-to-Mesenchymal Transition, Current Cancer Drug Targets 2013; 13 (9) . https://dx.doi.org/10.2174/15680096113136660096
DOI https://dx.doi.org/10.2174/15680096113136660096 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preclinical Studies of Alkylureas as Anti-HIV-1 Contraceptive
Current Pharmaceutical Design CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells
Current Pharmaceutical Design Novel Series of Coumarinyl Substituted-thiazolidin-2,4-dione Analogs as Anticancer Agents: Design, Synthesis, Spectral Studies and Cytotoxicity Evaluation
Anti-Cancer Agents in Medicinal Chemistry MEK Inhibitors: A Therapeutic Approach to Targeting the Ras-MAP Kinase Pathway in Tumors
Current Pharmaceutical Design Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design Application of a Deep Matrix Factorization Model on Integrated Gene Expression Data
Current Bioinformatics Chinese Medicine: A Novel Therapeutic Option for Pancreatic Cancer
Current Signal Transduction Therapy A Pan-Cancer Review of <i>ALK</i> Mutations: Implications for Carcinogenesis and Therapy
Current Cancer Drug Targets Evaluation of the Radioprotective Effects of Melatonin Against Ionizing Radiation-Induced Muscle Tissue Injury
Current Radiopharmaceuticals Preparation and Primary Bioevaluation of 99mTc-labeled-1-thio-β-D-Glucose as Melanoma Targeting Agent
Current Radiopharmaceuticals Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Evaluation of 99mTc Chelate-conjugated Bevacizumab
Current Radiopharmaceuticals Tumor-Targeted Inhibition by a Novel Strategy - Mimoretrovirus Expressing siRNA Targeting the Pokemon Gene
Current Cancer Drug Targets Ganoderma lucidum: A Potential for Biotechnological Production of Anti-Cancer and Immunomodulatory Drugs
Recent Patents on Anti-Cancer Drug Discovery Carbonic Anhydrase Based Biomarkers: Potential Application in Human Health and Environmental Sciences
Current Biomarkers (Discontinued) Isolation of a Mitogenic Agglutinin with Relatively High Thermostability from Seeds of the Variegated Shell Ginger
Protein & Peptide Letters How Immune-inflammatory Processes Link CNS and Psychiatric Disorders: Classification and Treatment Implications
CNS & Neurological Disorders - Drug Targets Recent Patents Involving Virus Nucleotide Sequences; Host Defense, RNA Silencing and Expression Vector Strategies
Recent Patents on DNA & Gene Sequences Novel Synthetic Pharmacophores Inducing a Stabilization of Cellular Microtubules
Current Cancer Drug Targets